What CVS Health Stock Was Telling You About Its Three-Dollar Earnings Prize

Before the stock surged, management laid out a turnaround plan for its Aetna unit that was so explicit, they practically put a price tag on it.

It’s easy to look at a stock chart after a 57% run and feel like you missed the party. Between Jun 30, 2025 and Jul 1, 2026, shares of CVS Health (CVS) did just that, leaving investors to wonder what they overlooked. But this wasn’t a sudden bolt from the blue. The story of the turnaround was assembling itself, quarter by quarter, in the company’s own words.

The evidence wasn’t buried in footnotes. It was the main event, a comeback narrative for its sprawling Aetna insurance business that management all but shouted from the rooftops.

How Bad Was The Aetna Problem?

Let’s rewind to late 2024. The picture was not pretty. The company’s Health Care Benefits segment, the engine of the Aetna acquisition, was sputtering. Management warned that the division could swing to an operating loss in 2024. As of its fiscal Q1 2025 report, the company’s overall revenue growth had slowed, and its net margin of 1.4% was sagging.

This was the moment of peak pessimism. But it was also the moment the new CEO earnings call, installed a new president and laid out a new playbook: prioritize profit, even if it meant shrinking.

What was the three-dollar promise management made?

Here’s the tell. In that same call, with the business under siege, the finance chief did something unusual. He quantified the prize for fixing it. He told investors there were “$3, $4 more of embedded adjusted EPS if we can get our Aetna business back to its target margins”

He wasn’t whispering. He was giving the market a roadmap. The plan involved making hard choices, like trimming membership in Medicare Advantage by 5% to 10% to shed unprofitable plans. A few months later, he repeated the math, noting that each point of margin recovery was worth another “$0.75 of adjusted EPS.”

When did the first real proof arrive?

The market seemed skeptical. But just before the stock began its run, the company delivered the first concrete evidence that the plan was working ahead of schedule. For its fiscal Q1 2025, the Health Care Benefits segment’s operating income jumped by over $1.2 billion from the prior year quarter. The medical benefit ratio, a key measure of profitability, came in at 87.3%, a sharp improvement.

The company promptly raised its full-year 2025 guidance. It also announced another tough but necessary decision: it would exit its money-losing individual ACA exchange plans, a move that would eliminate between $350 million and $400 million in projected annual losses.

The options market, for its part, seemed to be napping through the setup. In the weeks leading up to the surge, implied volatility actually eased, settling into the 31st percentile of its one-year range. Traders were pricing in calmer seas, just as the turnaround was gaining force.

The market was waiting for proof, but management had already shown its math.

How Do You Spot The Next CVS?

Honestly, most of these signals only look obvious in hindsight, and no one can read every earnings call and order book in real time. But one sign of a building surge IS visible as it happens: a company raising its own guidance. Our Guidance Momentum rankings track the S&P 500 names doing exactly that right now, where rising estimates meet rising prices. A guidance raise is only one signal, though. The Trefis High Quality (HQ) Portfolio weighs the full picture of quality across thousands of names, holds the 30 strongest, and sizes and rebalances them with rules. It has outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.